ArticleOncogene2000
Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 78 citations in OpenAlex.
- MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.Nature communications · 2022Trial
- Chromosomal instability as a predictive biomarker for recurrence risk following transurethral resection of NMIBC.Frontiers in oncology · 2026Article
- Association of ABO and Rhesus Blood Groups With Oral Cancers.Journal of clinical medicine research · 2025Review
- The Prognostic Role of CDK9 in Bladder Cancer.Cancers · 2022Article
- Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review.Translational andrology and urology · 2021Review
- VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer.BMC medical genomics · 2021Article
- Auxiliary diagnostic value of p16 amplification combined with the detection of heterozygous and homozygous loss for urothelial carcinoma.Oncology letters · 2018Article
- Genetic and Epigenetic Alterations in Bladder Cancer.International neurourology journal · 2016Review
- ABO blood groups in relation to breast carcinoma incidence and associated prognostic factors in Moroccan women.Medical oncology (Northwood, London, England) · 2016Article
- Canine urothelial carcinoma: genomically aberrant and comparatively relevant.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2015Article
- MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9.British journal of cancer · 2014Article
- Allele frequency of ABO blood group antigen and the risk of esophageal cancer.BioMed research international · 2014Article
- Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss-induced global genome instability.Genes, chromosomes & cancer · 2013Article
- Bladder cancer: a simple model becomes complex.Current genomics · 2012Article
- Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.Molecular cancer · 2008Article
- Molecular pathogenesis of bladder cancer.International journal of clinical oncology · 2008Review
- Chromosomal changes in uroepithelial carcinomas.Cell & chromosome · 2005Article
- Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.Journal of cancer research and clinical oncology · 2004Review
- Article
- The prognostic molecular markers in hepatocellular carcinoma.World journal of gastroenterology · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
In a previous study, loss of heterozygosity (LOH) of 28 chromosome 9 microsatellite markers was assessed on 139 Ta/T1 bladder tumors. LOH at one or more loci was detected in 67 tumors, 62 presenting subchromosomal deletions. One hundred and thirty-three of these patients have now been followed for up to 8 years. The purpose of the present study was to evaluate the potential biological significance of chromosome 9 deletions in superficial bladder tumors at initial diagnosis. High grade was associated with LOH (P=0.004). Large tumors carried more frequently 9p deletions (P=0.022). Female patients had more chromosome 9q LOH than male patients did (P=0.010). Chromosome 9 LOH at all loci was associated with an elevated risk of recurrence but four regions were associated with a particularly high risk of recurrence. Multivariate analysis taking into account grade, stage, size and number of tumors showed that tumors deleted in the regions 9ptr-p22, 9q22.3, 9q33, and 9q34 recurred significantly more rapidly than those without deletions (Recurrence rate ratio=2.32, 2.53, 2.52 and 2.43 respectively). Log-rank statistics comparing Kaplan-Meier survival curves for the same chromosomal regions confirmed the correlation (P=0.0002, 0.010, 0.002 and 0.009 respectively). Only four patients progressed to muscle-invasive disease. They all had extensive deletions on 9q but none had deletions at 9ptr-p22. This study suggests a link between chromosome 9 anomalies and recurrence of superficial bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.